Gufic Biosciences Ltd
NSE:GUFICBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gufic Biosciences Ltd
Net Income (Common)
Gufic Biosciences Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gufic Biosciences Ltd
NSE:GUFICBIO
|
Net Income (Common)
₹500.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹55.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹45.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹109.2B
|
CAGR 3-Years
37%
|
CAGR 5-Years
35%
|
CAGR 10-Years
11%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Net Income (Common)
₹46.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹22.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Gufic Biosciences Ltd
Glance View
Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-10-19. The firm operates through Pharmaceutical segment. The company has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash, and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole, Everolimus. Its Gufic Stridden includes Irvical and Eve.
See Also
What is Gufic Biosciences Ltd's Net Income (Common)?
Net Income (Common)
500.4m
INR
Based on the financial report for Dec 31, 2025, Gufic Biosciences Ltd's Net Income (Common) amounts to 500.4m INR.
What is Gufic Biosciences Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
23%
Over the last year, the Net Income (Common) growth was -39%. The average annual Net Income (Common) growth rates for Gufic Biosciences Ltd have been -15% over the past three years , 7% over the past five years , and 23% over the past ten years .
